Contrarian Investing Led Me to Salix Pharmaceuticals

NEW YORK (TheStreet) -- Every successful investor is a contrarian: If the sum of all wisdom on a stock says it is worth $100 today, that price captures not just today's value but some future value as well.

If you buy it in the expectation that is it worth more than that -- worth more than what hundreds of thousands of other investors believe -- that is, by definition, a contrarian point of view.

I know very few people that are entirely invested in U.S. small and mid-cap stocks, such as Salix Pharmaceuticals (SLXP). But I am. Why? Because I believe that if you are in the right place at the right time, then the market is a beautiful place to be right now. U.S. small and mid-cap stocks have been the sweet spot for the past 15 months.

I track 34 asset classes on a daily basis including gold, bonds and emerging markets. Here is my current ranking.

Data from Best Stocks NowApp

I see so many portfolios full of stocks that ran out of gas years ago. But they have big names and their CEOs says all the right things: Everything is going to get better. Just wait.

For them, investing is a faith-based initiative. I like value, performance and a good chart. My Best Stocks Now app tracks nearly 3,800 stocks. With so many to choose from, why do so many people choose the mediocre?

In addition to ranking asset classes, I rank 60 sectors in the market on a daily basis. Here is the current leader board.

Data from Best Stocks NowApp

If you liked this article you might like

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

Biotech Hits an Inflection Point

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

2 Small Biopharma Stocks on the Move

2 Small Biopharma Stocks on the Move